Lung Cancer Medical Breakthrough (OTC:BMOD)
Michael Vlaicu (August 22nd, 2009) Writes:
Biomoda, Inc.
(Public, OTC:BMOD)
StocksHaven Investments profiles one of the most promising up and coming small cap biotech companies, Biomoda Inc, which has established a medical breakthrough for early lung cancer detection. It is a development-stage company. The Company is an invitro diagnostics company that develops assays, or tests, to detect cancer. These assays are performed in clinical reference laboratories using body-fluid samples. This technology is based on a licensed patent from Los Alamos National Laboratories. The technology is based on a molecule that has an affinity to bind with cancer cells and it fluoresces red under ultra violet light. It is a porphyrin molecule. This technology works with a range of cell types. The Company is in the process of developing a line of assays for a variety of cancers based on adaptations of this technology. Biomoda’s first product
...ABC, Albuquerque City Attorney’s Office, America, Ampex, Angela Montoya, automated technology, Biomoda Inc., Biotechnology Associates, Bladder Cancer, Boston University, California, cancer, cancer detection;, Cancers, Cfo, chair, Cleveland, College of Santa Fe, Constance Dorian, Corporate Secretary and Director, Corporate Secretary and Director of Administration, Director of Administration, electronics, electronics engineer, Europe, executive and entrepreneur, Fda, General Counsel, Gordon Bennett, Gustave Roussy, insurance billing codes, John Cousins, John J. Cousins, Lab Technician, Los Alamos National Laboratories, Lung Cancer, lung cancers, Market Commentary, Medicare, member, Michael Vlaicu;, MIT, New England Journal, New Mexico, New Mexico Department of Veterans Services, North Carolina, Ohio, Optical Society of America and the New Mexico State Bar, oral cancer, Paris, President and a Director, President and CEO, prevention for cancer, public company CFO, San Diego State University, San Francisco, Securities And Exchange Commission, Stocks to Watch, StocksHaven Investments;, Subsequent product, technology works, the New England Journal of Medicine, Tim Zannes, Treatment Of Cancer, University of California, University of New Mexico, University of North Carolina, USD, Verrity Gershin, Vice President of Technical Operations, Wharton School, World Health Organization


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)





